Patients' Attitudes Toward and Experiences With Buprenorphine Treatment

Description

This study will disseminate five surveys collecting individual's attitudes and experiences during buprenorphine treatment for Opioid Use Disorder during the COVID-19 pandemic.

Conditions

Opioid-use Disorder, Acceptability of Health Care, Opioid-Related Disorders

Talk to us

Study Overview

On this page

Study Details

Study overview

This study will disseminate five surveys collecting individual's attitudes and experiences during buprenorphine treatment for Opioid Use Disorder during the COVID-19 pandemic.

Exploring the Attitudes and Experiences of Patients Engaged in Buprenorphine Treatment During the COVID-19 Pandemic

Patients' Attitudes Toward and Experiences With Buprenorphine Treatment

Condition
Opioid-use Disorder
Intervention / Treatment

-

Contacts and Locations

Cambridge

CHA Center for Mindfulness and Compassion, Cambridge, Massachusetts, United States, 02141

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Participants must be 18 years of age or older.
  • * Participants report currently having a legal prescription for buprenorphine for opioid use disorder.
  • * Participants must have a past or present opioid use disorder.
  • * Participants must currently reside in the state of Massachusetts.
  • * Participants must be able to comprehend the English language.
  • * Unable to complete an online survey.
  • * Unable to complete a verification step that ensures bots are not used to complete survey.
  • * Complete a survey with no variation suggesting they did not read the survey.

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

Cambridge Health Alliance,

Zev Schuman-Olivier, MD, PRINCIPAL_INVESTIGATOR, Cambridge Health Alliance

Joseph Rosansky, STUDY_DIRECTOR, Cambridge Health Alliance

Study Record Dates

2025-03-20